

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	09/782,804	02/13/2001	Motasim Sirhan	020460000940	9572
	20350 7	7590 . 07/17/2002			
	TOWNSEND AND TOWNSEND AND CREW, LLP			EXAMINER	
	TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834		PHAN, HIEU		
				ART UNIT	PAPER NUMBER
				3738	
				DATE MAILED: 07/17/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		09/782,804	SIRHAN ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Hieu Phan	3738				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1)	Responsive to communication(s) filed on 13 F	ebruary 2001 .					
2a)	This action is FINAL . 2b)⊠ Thi	s action is non-final.					
3)							
Disposit	Disposition of Claims						
4)🖂	Claim(s) 1-60 is/are pending in the application.	•					
	4a) Of the above claim(s) 1-36 is/are withdrawn from consideration.						
5)	5) Claim(s) is/are allowed.						
6)⊠	6)⊠ Claim(s) <u>37-54 and 57-60</u> is/are rejected.						
7)🖂	Claim(s) 55 and 56 is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement. Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11)	11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority (ınder 35 U.S.C. §§ 119 and 120						
13)	13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)	a) All b) Some * c) None of:						
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14) 🗌 A	4) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
	a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)							
2) Notice	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>5 a</u>	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/782,804

Art Unit: 3738

Response to Election/Restriction

1. Applicant's election without traverse of Group II, claims 37-59, and added claim 60 in Paper No. 9 is acknowledged. Non-elected claims 1-36 are withdrawn from further consideration.

Specification

- 2. The disclosure is objected to because of the following informalities: on page 3 lines 18-
- 21 there are blank spaces, which appears to be missing some information.

Appropriate correction is required.

Double Patenting

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 52-60 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 52-60 of copending Application No. 09/782804. Although the conflicting claims are not identical, they are not

Application/Control Number: 09/782,804

Art Unit: 3738

patentably distinct from each other because method of using mizoribine and methylprednisolone to inhibit restenosis in a blood vessel following recanalization of the blood vessel.

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 6. Claims 60 and 38-51 are rejected under 35 U.S.C. 102(b) as being anticipated by Domb et al. (U.S. Patent 5,512,055).

Domb et al. disclose a stent with polymeric coatings with methylprednisolone as is claimed (Abstract, column5 lines 34-46 and column 6 lines 37-59).

7. Claims 37, 52-51 and 57-59 are rejected under 35 U.S.C. 102(b) as being anticipated by Gregory et al. (U.S. Patent).

Gregory et al. disclose method for treating hyperproliferation vascular disease by administering MPA and Mizoribine as is claimed (Abstract, column 3 lines 44-52 and column 24-31).

Allowable Subject Matter

8. Claims 55 and 56 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Application/Control Number: 09/782,804

Art Unit: 3738

in a same

Conclusion

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hieu Phan whose telephone number is 703-308-8969. The examiner can normally be reached on Monday-Friday from 8am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine M McDermott can be reached on 703-308-2111. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3590 for regular communications and 703-305-3590 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0873.

Hieu Phan Examiner Art Unit 3738

CORRINE McDERMOTT SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 3700